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ABSTRACT
Introduction: Seasonal inﬂuenza vaccination is
recommended for all individuals aged 65 years and
over and in individuals younger than 65 years with
comorbidities. There is good evidence of vaccine
effectiveness (VE) in young healthy individuals but less
robust evidence for effectiveness in the populations
targeted for inﬂuenza vaccination. Undertaking
a randomised controlled trial to assess VE is now
impractical due to the presence of national vaccination
programmes. Quasi-experimental designs offer the
potential to advance the evidence base in such
scenarios, and the authors have therefore been
commissioned to undertake a naturalistic national
evaluation of seasonal inﬂuenza VE by using data
derived from linkage of a number of Scottish health
databases. The aim of this study is to examine the
effectiveness of the seasonal inﬂuenza vaccination in
the Scottish population.
Methods and analysis: A cohort study design will be
used pooling data over nine seasons. A primary care
database covering 4% of the Scottish population for
the period 2000e2009 has been linked to the national
database of hospital admissions and the death register
and is being linked to the Health Protection Scotland
virology database. The primary outcome is VE
measured in terms of rate of hospital admissions due
to respiratory illness. Multivariable regression will be
used to produce estimates of VE adjusted for
confounders. The major challenge of this approach is
addressing the strong effect of confounding due to
vaccinated individuals being systematically different
from unvaccinated individuals. Analyses using
propensity scores and instrumental variables will be
undertaken, and the effect of an unknown confounder
will be modelled in a sensitivity analysis to assess the
robustness of the estimates.
Ethics and dissemination: The West of Scotland
Research Ethics Committee has classiﬁed this project
as surveillance. The study ﬁndings will be
disseminated in peer-reviewed publications and
presented at international conferences.
INTRODUCTION
Each year, inﬂuenza causes substantial
morbidity and mortality, particularly in
people aged 65 years and over and those with
underlying serious comorbidities. In the
USA, it has been estimated that inﬂuenza is
responsible for 186000 excess hospital-
isations and 44000 excess deaths.
1 National
vaccination strategies represent a potentially
important approach to reduce both inﬂu-
enza-related illness and death, hence the
considerable investment in this approach
in many parts of the world. Although
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ARTICLE SUMMARY
Article focus
- Study protocol for a cohort study to investigate
the effectiveness of the seasonal inﬂuenza
vaccine in the general population.
Key messages
- Seasonal inﬂuenza is responsible for substantial
global morbidity and mortality, particularly in
high-risk populations. Uptake rates for seasonal
inﬂuenza vaccine remain suboptimal.
- As randomised controlled trials are no longer
feasible to assess VE, quasi-experimental
methods can be used in their place.
Strengths and limitations of this study
- The study population comprises a large unbiased
sample of the general population.
- We are developing a unique linked national
database, which contains anonymised individual
patient-level data from general practices, hospi-
tals, virology investigations and the death
register.
- Our analysis plan takes a robust and compre-
hensive approach to the well-described problem
of confounding in VE studies.
- As this is an observational study, residual
confounding may still be present despite the
comprehensive approach we plan to take to deal
with this.
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Open Access Protocolvaccination rates in those over 65 in Scotland are
a reasonable 75.0% (season 2009/2010), the rates in at-
risk groups younger than 65 years remain low (53.4% in
season 2009/2010) despite widely promulgated guide-
lines and incentivised vaccination programmes.
2 There
is good evidence of the beneﬁts of the vaccine in young
healthy adults and children,
3 but a scarcity of reliable
estimates from randomised controlled trials in at-risk
populations.
4 There is also limited evidence from
observational research, which has only shown effective-
ness of vaccination in selected groups of patients, for
example, those aged over 65 years
5 or those in at-risk
groups for single inﬂuenza seasons.
6 Furthermore, these
studies may have been prone to bias and residual
confounding.
47This may explain, in part, the reason for
lower vaccine uptake rates.
Randomised controlled trials offer the best opportu-
nity to produce unbiased estimates of vaccine effective-
ness (VE). However, given that inﬂuenza vaccination
programmes exist in most developed countries, this
form of study design is now impractical and is viewed by
many in the medical community as unethical.
8 Obser-
vational studies are an alternative to investigate VE.
However, an individual’s decision to attend the local
general practice surgery for vaccination may be a marker
of healthier behaviour generally, as well as identifying
more highly educated individuals who are more aware of
and more likely to act on recommendations for their
own health. These individuals may be less likely to die
from any cause or be admitted to hospital, thus inducing
a spurious relationship between vaccination status and
the outcome (ie, positive confounding). Similarly,
patients who are very frail and unable to attend the
general practice surgery may be less likely to be vacci-
nated, but much more likely to die or be admitted to
hospital.
9 This phenomenon is also known as the
‘healthy vaccine effect’.
Standard methods of adjustment for confounders are
likely to be inadequate to control for confounding
due to the healthy vaccine effect. This can result in
excessive estimates of VE in observational studies using
non-inﬂuenza-speciﬁc outcomes due to residual
confounding. A number of methods can be used to try
and address this problem, including quasi-experimental
study designs and advanced statistical methods. In
addition, an analysis framework has been proposed to
identify residual confounding when undertaking VE
studies using observational methods.
10
This research aims to examine the effectiveness of the
seasonal inﬂuenza vaccine while addressing the meth-
odological challenges outlined above of using observa-
tional data. We will have access to a unique set of linked
databases, which contain individual patient-level data
relating to primary healthcare, acute hospital care,
virological laboratory tests and mortality. In contrast to
previous observational studies, these rich data sources
provide information on a large number of potential
confounders and highly speciﬁc laboratory outcome
measures in a study cohort sampled from the general
population. Our assessment of the effectiveness and
impact of the seasonal inﬂuenza vaccination programme
therefore offers potentially large societal beneﬁts both
for Scotland, the UK, and for advancing the interna-
tional evidence base.
AIMS AND OBJECTIVES
We aim to examine the effectiveness of the seasonal
inﬂuenza vaccination in individuals registered with
a national sample of general practices in Scotland. More
speciﬁcally, the objectives of this study are to (1) report
vaccine uptake in the relevant at-risk populations for
whom vaccination is recommended in the UK; (2) eval-
uate VE measured in terms of the following outcomes:
rate of hospital admissions due to respiratory illness
(primary outcome), rate of primary care consultations
due to respiratory illness, risk of death due to respiratory
illness and risk of laboratory-conﬁrmed inﬂuenza infec-
tion and (3) assess the degree of and adjust for residual
confounding in our estimates using analyses incorpo-
rating propensity scores, instrumental variables and the
effect of a hypothetical unknown confounder.
METHODS
Study design and population
A cohort study design will be used to assess VE. Vaccine
uptake will be reported using serial cross-sectional
surveys. Data extracted from 35 general practices of the
sentinel surveillance network in Scotland, the Practice
Team Information network, will be used. Participating
practices cover a 4% sample of the Scottish population
(n¼209452 registered alive in 2009). The population
targeted for inﬂuenza vaccination comprises all patients
aged 65 years and older (approximately 15% of the
general population, n¼28241 in the sample) and those
aged younger than 65 years deﬁned as being in an at-risk
group on the basis of pre-existing illness (n¼w33000,
18% of younger than 65-year-olds).
11 The estimates for
proportion of patients younger than 65 years in an at-risk
group were taken from our recent VIPER study investi-
gating the effectiveness of the 2009 H1N1 pandemic
inﬂuenza vaccine.
12 Each patient will contribute person-
time to each inﬂuenza season while alive and registered
with a participating general practice. The primary care
database was linked to the Scottish acute hospital
discharge database and Scottish death register as part of
the VIPER project.
12 In addition, a linkage of these data
sets to the Health Protection Scotland virology database
to determine laboratory-conﬁrmed inﬂuenza infection is
underway (due to be completed on 1 February 2012).
Databases
Acute hospital discharge database
The Information Services Division, National Services
Scotland, maintains a database of all acute hospital
discharges in Scotland, known as the Scottish Morbidity
Record 1. All inpatient and day case episodes of care for
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database. The database is subject to regular validation
checks, and the most recent quality assurance report
indicated good levels of accuracy (>90%) for the ﬁelds
used in this study.
13 Diagnostic information is recorded
using International Classiﬁcation of Disease version 10
(ICD-10). There are up to six ﬁelds that can be used to
record diagnoses, with one allocated as the main reason
for admission. Scottish Morbidity Record 1 is linked
routinely by Information Services Division to the
Scottish death register using patient characteristics in
a probabilistic matching algorithm with a high degree of
accuracy.
14 15
Primary care database
Almost all individuals resident in Scotland are registered
with a primary care practice, which provides healthcare
services free of charge. Virtually all specialist hospital
care services are also free of charge, usually obtained
through referral from primary care or, in emergency
situations, through patients attending an emergency
department. Primary care-based physicians provide or
coordinate much of the care of patients discharged back
into the community by secondary and tertiary care
services. The primary care database was linked to the
other databases using probabilistic linkage. Linkage
accuracy was high due to the high quality and number of
patient identiﬁers available from the primary care data-
base. Completeness of capture of contacts and accuracy
of clinical event coding (using Read codes) has been
found to be above 91% among the study practices.
16 17
The electronic recording of long-term prescribing
information by primary care has also been found to be
both accurate and complete.
18
Death register
Details from death certiﬁcates issued for all deaths in
Scotland are recorded in the death register, maintained
by National Records Scotland.
19 Cause of death has been
routinely coded using ICD-10 since 2000.
Health Protection Scotland virology database
The Scotland-wide unique patient identiﬁer, the
Community Health Index number, is being used to link
records in the virology database to the other databases.
There may be fewer virology records with adequate
patient identiﬁable information to allow linkage for the
years 2000e2005 of the study period. This is actively
being investigated by coinvestigators.
Study period
Data from 1 September 2000 to 31 August 2009 will be
used. This will allow analysis of nine inﬂuenza seasons
(2000/2001 to 2008/2009). Each year (1 September to
31 August) will be divided into four periods (ﬁgure 1).
The inﬂuenza season will be deﬁned for each year using
national inﬂuenza surveillance data.
20 The start of the
period will be from the date of the ﬁrst inﬂuenza isolate
reported by Health Protection Scotland each year. The
end of the inﬂuenza season will be the date of the last
inﬂuenza isolate with an additional 14-day period for
complications. The pre-inﬂuenza period will be deﬁned
as starting from 1 September each year until the date of
the ﬁrst inﬂuenza isolate. The post-inﬂuenza period will
start 14 days after the last inﬂuenza isolate and end on 31
May each year. The ‘non-inﬂuenza’ period for each year
will be from 1 June to 31 August (ﬁgure 1).
Exposure deﬁnition
Vaccination will be used to deﬁne exposure status if it is
given at a time point between the start of the pre-inﬂu-
enza season (1 September) and the end of the inﬂuenza
season (ﬁgure 1). An individual will be deﬁned as
vaccinated 14 days after the seasonal inﬂuenza vaccine
has been administered.
21 The time period from the ﬁrst
day of the inﬂuenza season to day 14 post-vaccination
will be deﬁned as ‘unexposed’ and the period from day
14 post-vaccination until the end of the inﬂuenza season
will be deﬁned as ‘exposed’. Therefore, those vaccinated
between the start of the pre-inﬂuenza period up until
14 days before the inﬂuenza season will be deﬁned as
‘exposed’ for the duration of the inﬂuenza season.
Outcomes
VE should ideally be measured using inﬂuenza-speciﬁc
outcomes in each of the databases. However, it is likely
that ICD codes or Read codes referring to inﬂuenza-
speciﬁc outcomes are underused by clinicians and
coders, thereby reducing the sensitivity and power of the
primary analysis. For this reason, codes for acute respi-
ratory diseases were chosen as primary outcome measures
as they would capture a substantial proportion of
Figure 1 Relationship of ﬁrst
inﬂuenza season (2000e2001) to
pre-, post- and non-inﬂuenza
season periods. Baseline
characteristics for each patient are
determined on 1 September each
year. The earliest date of inﬂuenza
vaccination varied for each
inﬂuenza season but always
occurred after 1 September.
Pre-influenza 
season 1
Influenza 
season 1
Post-influenza 
season 1
1 Sep 2000
Date of first 
influenza isolate
1 Jul 2001
Non-influenza 
season 1
1 Sep 2001
Pre-influenza 
season 2
Baseline 
characteristics 
determined for 
season 1 
Baseline 
characteristics 
determined for 
season 2 
Date of last 
influenza isolate 
+ 14 days
Vaccination 
occurs during 
this period
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Laboratory-conﬁrmed inﬂuenza infection will be a highly
speciﬁc outcome and will be calculated on a subgroup of
the study population (see Laboratory methods section).
VE will be calculated by subtracting the rate ratio (RR)
or odds ratio (OR) of vaccinated compared with unvac-
cinated patients from 1 (ie, VE¼(1 OR)3100% or VE¼
(1 RR)3100%) for each of the following outcome
measures:
a. Hospital discharge data: rate of emergency hospital-
isations with a diagnosis of inﬂuenza or pneumonia
(primary measure of VE).
b. Primary care data: rate of consultations in primary
care for inﬂuenza-like illnesses and acute respiratory
infection.
c. Death register: deaths due to inﬂuenza, pneumonia
or chronic obstructive pulmonary disease (COPD).
d. Health Protection Scotland Virology Database: labo-
ratory-conﬁrmed inﬂuenza.
Additional sensitivity analyses will be undertaken using
less-speciﬁc outcomes (all-cause mortality, emergency
admission to hospital for any reason) as well as the
inﬂuenza-speciﬁc outcomes (deaths due to inﬂuenza,
hospital admissions due to inﬂuenza). These analyses
will be part of the framework to assess bias (see below).
A number of secondary analyses will be undertaken
using other outcomes. The effect of vaccination status
on hospital admissions and deaths relating to cardio-
vascular and cerebrovascular events as a composite
outcome will be analysed. In addition, exploratory
analyses will be undertaken to assess the effect of vacci-
nation status on outcomes for which it would not be
expected to have an effect, for example, appendicitis or
trauma. This approach of using an alternative outcome
as a negative control has been shown to be a useful
method for detecting residual bias.
22
Confounding factors
Individuals who are vaccinated are likely to be different
from those who are unvaccinated. An extensive list of
individual-level and practice-level characteristics will be
included as confounders in the analyses. These will be
deﬁned in each year on the ﬁrst day of the pre-inﬂuenza
season (1 September). Practice effects will be accounted
for using multilevel methods.
Demographics
Sex, age-band (0e4, 5e14, 15e44, 45e64, 65e74 and
75+) and socioeconomic status will be included in all
analyses; socioeconomic status will be measured using
quintiles of the Scottish Index of Multiple Deprivation:
1¼most afﬂuent and 5¼most deprived). Scottish Index
of Multiple Deprivation is an area-based measure of
deprivation derived from seven domains including
income, employment and education.
23
At-risk groups
At-risk patients are those with certain comorbidites for
whom seasonal inﬂuenza vaccination is indicated.
Patients will be deﬁned as high risk according to
national guidance
11 if they have one or more of the
following conditions:
< chronic heart disease,
< chronic kidney disease (including renal transplanta-
tion),
< chronic liver disease,
< chronic neurological disease,
< chronic respiratory disease,
< conditions or drugs causing impaired immune
function and
< diabetes.
Chronic diseases
Comorbidity will be deﬁned by the 17 disease categories
that constitute the Charlson Comorbidity Index.
24 This
index has been validated in a number of different
databases using codes from healthcare databases.
25 A
recent study has mapped Read codes from a UK general
practice database to the relevant Charlson comorbid
disease groups, resulting in a model that performed well
in the prediction of 5-year mortality.
26 These codes will
be used to identify comorbidities that are present in
a patent’s record prior to the start of each pre-inﬂuenza
season (1 September). The number of repeat prescrip-
tion items issued in the previous 12-month period will be
used as an additional measure of comorbidity. Measures
of previous healthcare resource use will also capture
other aspects of chronic health status.
Smoking status
This will be derived from primary care data (current
smoker, ex-smoker, non-smoker) and determined on 1
September each year.
Previous vaccinations
A variable will be included for patients who have
received seasonal inﬂuenza vaccination in the previous
season to account for the possibility of persisting VE in
the subsequent year.
27 Adjustment for previous pneu-
mococcal vaccination at any time in the primary care
record prior to 1 September each year will also be
undertaken, which will be particularly important for
less-speciﬁc outcome measures such as all-cause death.
Previous healthcare utilisation
The number of general practice consultations in the
previous 12 months will be used as a measure of
healthcare utilisation. Number of emergency admissions
to hospital for any cause during the previous 12 months
will be used as a marker of severity of chronic health
status.
Functional status
There is no direct measure of functional status made in
any of these national databases. However, individuals
who require a home visit when consulting a general
practitioner rather than attending the practice will be
identiﬁed. This will be used as a proxy marker for poor
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dent in some form of institutional care setting may be
identiﬁable from the primary care database. This will
also be used as an indicator of more severe functional
limitation.
Laboratory methods
Not all patients receiving vaccination will have been
swabbed for inﬂuenza. The majority of Practice Team
Information general practices are involved in the Health
Protection Scotland sentinel swabbing scheme, whereby
practices are encouraged to submit ﬁve swab samples per
week to the West of Scotland Specialist Virology Centre
(for multiplex polymerase chain reaction testing for
a range of respiratory pathogens) on any patient
presenting for consultation in the practice for inﬂuenza-
like illness and acute respiratory infections across all
ages. Crucially, this is independent of whether the
individual has or has not been vaccinated.
Subgroups for stratiﬁed analyses
The primary analysis will be performed using the whole
cohort. A stratiﬁed analysis will be undertaken for those
aged 65 years and older and those aged younger than
65 years old and by risk groups. This will allow VE to be
assessed in more homogeneous subgroups and to check
for effect modiﬁcation across strata. Further subgroup
analysis will be performed by restricting the study cohort
to the main population group for whom the national
inﬂuenza vaccination programme is targeted: those aged
65 years or older together with those aged younger than
65 years in an at-risk group.
11 It is likely that these
analyses in subgroups will be underpowered, in partic-
ular in the younger than 65-year age group for whom
event rates will be lower. Further stratiﬁed analyses will
be undertaken as part of the framework to assess residual
confounding (see section below).
Methods to further adjust for confounding
We plan to take a comprehensive approach to dealing
with confounding due to the healthy vaccine effect in
our study. This will include the use of complex statistical
methods including propensity score analysis, instru-
mental variable analysis and modelling a hypothetical
unmeasured confounder. These are considered in more
detail below.
Propensity scores
Propensity scores are a well-described method to reduce
the effect of strong confounding, such as confounding
by indication.
28 We will develop a propensity score to
predict the likelihood that a patient receives the seasonal
inﬂuenza ﬂu vaccine. This will allow for a better
comparison to be made between vaccinated and unvac-
cinated groups. A logistic regression model will be
constructed with vaccination status as the outcome in
order to produce a score of the propensity to be vacci-
nated. The covariates in the model will be derived from
available patient- and practice-level characteristics, which
we consider to be clinically relevant to the probability of
receiving the vaccination.
Instrumental variables
Instrumental variable analyses are well established in
non-healthcare settings such as econometrics as
a means of adjusting for unmeasured confounding.
29 An
instrumental variable is a factor related to exposure
status (ie, vaccination status), which does not have an
independent effect on outcome other than by ways
mediated through the exposure. Furthermore, an
instrumental variable should not be related to any vari-
ables that confound the relationship between exposure
and outcome. There are no instrumental variables that
have been established as appropriate for analyses of
VE.
30 For this reason, we will explore a number of vari-
ables that may fulﬁl the above criteria on a conceptual
level.
Sensitivity analysis for unmeasured confounding
We will carry out a sensitivity analysis on the results of
our primary analysis to explore the impact of an
unmeasured confounding factor on the estimate of
VE.
31 This will allow us to account for confounders such
as poor functional status which is, as noted above,
incompletely recorded in the national databases. This
method assumes that the unmeasured confounder is not
associated with the measured confounders in the model
and is therefore likely to overestimate the impact of the
unmeasured confounder.
32
Framework for detecting residual confounding
As described earlier, we will undertake additional anal-
yses to identify the presence of residual confounding.
This has been recommended as part of an analytical
framework when reporting VE using observational study
designs.
33 We will assess the variation in VE using the
following criteria:
1. Seasonality: stratiﬁcation on season is more important
when VE is measured using non-speciﬁc outcomes.
Each year of observation will be partitioned into four
periods: non-inﬂuenza period, pre-inﬂuenza season,
inﬂuenza season (when inﬂuenza virus is circulating)
and post-inﬂuenza season (ﬁgure 1). Maximal VE
should be seen during the inﬂuenza season. The
vaccine should have no effect on outcome in the
pre-inﬂuenza and non-inﬂuenza seasons. The non-
inﬂuenza season will use vaccination status from
the previous inﬂuenza season. This is to minimise
the bias that might occur when vaccination status
is applied retrospectively. This retrospective applica-
tion of vaccine status would include patients who
die during the preceding non-inﬂuenza season as
unvaccinated, despite the fact that they would not
have survived long enough to be eligible for
vaccination.
2. Vaccine match: VE should be lower in years during
which the inﬂuenza vaccine was a poor match for the
circulating virus.
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years during which the circulating virus caused a large
excess mortality during the inﬂuenza season.
4. Age: it is thought that inﬂuenza vaccine is less effective
in the oldest age groups due to immune senescence.
33
If this assumption is correct, VE should be lowest in
the oldest subgroup. A stratiﬁed analysis on age
groups will be undertaken to assess for this effect.
5. Speciﬁcity of outcome measure: VE should be
greatest for the most speciﬁc outcome (laboratory-
conﬁrmed inﬂuenza infection) and lowest for the
less-speciﬁc outcomes (all-cause mortality). In addi-
tion to the primary analysis, in the three non-
laboratory databases, we will undertake analyses
using the more inﬂuenza-speciﬁc outcomes (inﬂu-
enza-coded deaths, hospital admissions and primary
care attendances) and less-speciﬁc outcomes (all-
cause deaths, any emergency hospital admissions
and any primary care attendances).
Statistical analysis
Baseline characteristics will be summarised by vaccina-
tion status for the whole cohort using mean, median or
proportion where appropriate together with a measure
of dispersion. Missing data will be reported for each
variable. A 5% signiﬁcance level will be used for
hypothesis tests for the primary outcome. All p values
will be two sided. All analyses will be undertaken in R.
CIs for the RR and tests of the differences between two
rates will be carried out using the ‘midp method’ in the
RR function and rate2by2.test function, respectively,
using the ‘epitools’ package in R.
34 For small samples,
CIs for the RR will be estimated using the Excel work-
book. Effect modiﬁcation will be assessed across age
groups, year and season by entering an interaction term
into models. A complete case analysis will be the primary
analysis. Multiple imputation using chained equations
will be used, if necessary, to perform analyses on
imputed data sets to assess the effect of missing data on
VE estimates.
35
Annual and pooled analyses
We will initially analyse each of the nine inﬂuenza
seasons from 2000/2001 to 2008/2009 separately to
calculate the VE for each season. We plan to test the
homogeneity of the vaccine effect over the seasons, and
if appropriate, pool the data to give a more powerful
analysis than would be obtained using a simple aggre-
gation of data. In the pooled analysis, we will account for
the within-person correlation resulting from repeated
measures on the same individual in subsequent seasons
by the use of generalised estimation equations or an
adjustment for clustering. This is likely to be more
computationally efﬁcient than hierarchical models. For
the pooled analysis, we will be able to incorporate the
effects of time and also to let the vaccine effect vary with
year yet keeping the effect of the explanatory variables
constant over time. If a pooled analysis is not considered
appropriate, for example, if there is evidence of
substantial heterogeneity in the VE over seasons, then we
will use meta-regression models to try to explain this
heterogeneity.
Vaccine uptake
ORs (adjusted for age, sex and deprivation) will be
calculated for differences in vaccine uptake rates between
different groups of patients (sex, age, deprivation
quintiles and at-risk groups).
Vaccine effectiveness
Crude and adjusted VE estimates will be reported for
each outcome. VE estimates will be calculated for the
cohort as a whole and stratiﬁed using the subgroups
speciﬁed above. We will use the VE outcomes above to
calculate numbers needed to vaccinate to prevent one
swab-determined inﬂuenza infection, hospitalisation,
consultation and death. A person-time denominator will
be used for general practice consultations, hospital
admissions and death. Follow-up time will be censored at
death from any cause for consultations and admissions.
Hospital admissions and consultations can have multiple
events and each event will be counted.
Hospitalisations and primary care consultations
The ratio of the number of admissions to hospital per
person-time during the post-vaccination period
compared with the number of admission to hospital per
person-time during the pre-vaccination period will be
calculated. The unadjusted estimate of VE will be
calculated as (1 RR)3100%. Adjusted RRs of VE for
prevention of hospitalisation will be derived from
Poisson regression models, adjusting for the
confounders listed above. Similar methods will be used
to estimate VE for primary care consultations.
Deaths
The OR of deaths in the vaccinated group to deaths in
the unvaccinated group will be calculated; these will be
both unadjusted and adjusted for the confounders listed
above. VE will be calculated as (1 OR)3100%.
Laboratory-conﬁrmed infection
For VE, using information from linked virological swab
data, a logistic regression model will be ﬁtted adjusting
for the confounders listed above. VE will be measured by
comparing swabs taken after vaccination with swabs
taken before vaccination for all vaccinated individuals
and second by comparing swabs taken after vaccination
among those vaccinated to swabs taken among those
never vaccinated. VE will be calculated as (1 OR)3100.
Statistical methods to further adjust for confounding
Propensity score
We will undertake analyses incorporating propensity
scores using three different methods: regression
(including propensity score as a covariate), stratiﬁcation
(based on quintile of propensity score) and matching
(vaccinated and non-vaccinated patients individually
matched by propensity score). The model will be
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factors that inﬂuence propensity to be vaccinated. The
following covariates will be included in the model: age,
sex, socioeconomic status, comorbidities for which
vaccination is indicated (see above), comorbidities
included in the Charlson Index, smoking status,
previous vaccinations, functional status/frailty, number
of primary care consultations in previous year, number
of hospitalisations in previous year, number of repeat
prescription items in previous year, practice type, overall
practice deprivation, practice vaccination rate and
inﬂuenza season.
Instrumental variable analysis
We will consider the following variables as potential
instrumental variables: previous antacid prescription,
previous thyroxine prescription, gout and screening
attendance. We will assess whether these variables fulﬁl
the following criteria for use as an instrumental variable:
association with vaccination status (exposure), no asso-
ciation with outcome other than thorough exposure and
no association with confounding variables. The rationale
for selecting these variables is that each may increase the
likelihood of a patient being opportunistically vacci-
nated while attending the general practitioner but
should not be related to the risk of contracting inﬂu-
enza. If a suitable instrumental variable is found, anal-
yses will be undertaken to produce VE estimates adjusted
for the measured confounders and the instrumental
variable. We will use a two-stage estimation method with
logistic models used to combine the two equations.
Modelling an unmeasured confounder
Death rates and hospital admission rates are likely to be
highest in the frailest members of the study population.
As these patients are less likely to seek vaccination, it has
been suggested that inadequately measured frailty may
explain some of the VE measured in observational
studies.
7 9 As we may have been unable to fully account
for frailty, which has been deﬁned in recent studies,
36 37
we will use estimates from published data to model this
unmeasured (or inadequately measured) confounder in
a sensitivity analysis. We will assume that prevalence of
frailty varies from 5% to 20% in those aged 65 years or
older,
36 37 that frail individuals are two to four times
more likely to be hospitalised or die
5 and assume that
frail individuals have a 50% lower probability of being
vaccinated.
38
Sample size
In our related VIPER study,
12 the VE estimates were of
the order 50% or greater, depending upon the end
point, even though the follow-up time was limited to
90 days after vaccination. The power calculations are
based upon a comparison of rates, assuming a Poisson
distribution, for consultations, hospitalisations and
deaths. Baseline rates are derived from previous studies
for hospitalisations and consultations in VIPER
12 and
surveillance data from the Pandemic Inﬂuenza Primary
Care Reporting system.
39 For mortality, rates are derived
from statistics published by National Records Scotland.
40
For the virological response, the power is derived from
the comparison of two proportions and baseline swab
positivity derived from Hardelid et al.
41 In all cases, an
adjustment for the effective population size is made
using design effects, estimated from Pandemic Inﬂuenza
Primary Care Reporting and the VIPER study, ranging
from 1.07 to 1.15 associated with the clustering of
patients within general practices. Power is calculated for
a single year and also for the whole 9-year period,
assuming that the vaccine effect is similar in all seasons.
For hospitalisations, deaths and virology we anticipate
using a 6-month comparison period within each season,
while for general practice consultations, a 1-month
period is used in the power calculation, although in the
analysis a longer time will be used. Power calculations
are summarised in table 1.
Table 1 Summary of power calculations for each outcome measure
Rate/100000 % Vaccinated
One season Over 9 seasons
VE Power VE Power
Hospitalisatons
Inﬂuenza 50 15 70 83 30 79
Inﬂuenza and pneumonia 275 15 40 86 15 85
Mortality
Respiratory only (65+ only) 750 60 50 86 20 92
All causes (65+ only) 5000 60 20 83 7 85
Primary care consultations
ILI consultations (rate/week) 30 15 40 84 15 82
Percent positive % Vaccinated VE Power VE Power
Virology
800 swabs per annum 30 15 45 87 15 83
400 swabs per annum 30 15 60 85 20 79
Power calculations are presented for one season and for pooling across nine seasons. Allowance has been made for the effect of clustering of
patients within general practices.
ILI, inﬂuenza-like illness; VE, vaccine effectiveness.
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Hospitalisations for inﬂuenza are rare at 50/100000/
year and for a single year we will have a power of 83% to
detect a 70% vaccine effect. Combining the 9 years of
data gives a power of 80% for a 30% vaccine effect. By
aggregating both inﬂuenza and pneumonia hospital
admission, the underlying rate increases over ﬁvefold,
and the power to detect a vaccine effect of 40% in
a single year is 86% and 85% for a 15% vaccine effect
over 9 years (table 1).
Mortality
All cause
Among people over 65 years, the death rate from
all causes in Scotland is 5000/100000. Assuming that
55%e75% of the age group are vaccinated, then this
study has a power in excess of 80% to detect a difference
of 20% or more in the proportions of vaccinated and
unvaccinated individuals dying over a period of
6 months. Assuming similar vaccine effect in each of the
9 years, the power approaches 90% to detect a 7%
vaccine effect.
Respiratory deaths
Reductions in respiratory deaths will also be included as
a compound outcome. These account for 15% deaths.
The estimated 30% reduction in mortality between
vaccinated than unvaccinated individuals is a conserva-
tive estimate based on data from previous research (eg,
Nichol et al
5 found a 58% reduction in mortality between
vaccinated and unvaccinated in over 65s). For the
compound respiratory deaths end point, we will have at
least 80% power to detect a 50% mortality reduction in
a single year and over 90% power to detect a 20%
vaccine effect over the 9-year period.
Primary care consultations for inﬂuenza-like illness and
acute respiratory infection
Consultation rates for inﬂuenza-like illnesses and
acute respiratory infections are of the order of 30/
100000/day and over the period of 1 month the whole
cohort will have a power of 84% to detect a difference of
40% in consultation rates between the vaccinated and
unvaccinated. Extending to nine seasons, the power is
over 80% to detect a 15% vaccine effect. Extending the
follow-up time each season will increase the power.
Vaccine uptake is assumed to be at 15% of the whole
population.
Laboratory-conﬁrmed inﬂuenza infection
During the period of inﬂuenza activity, swab positivity for
inﬂuenza is around 30%. If there are 800 swabs collected
per year and there is a 15% vaccine uptake, then
a vaccine effect of 45% can be detected in a single season
with a power of 87% and a vaccine effect of 15%
detected over 9 years with a power of 83%. With fewer
swabs taken, the power is smaller though even if only 400
swabs are taken per year, a vaccine effect of 20% can be
detected with just under 80% power.
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